Clinical development data from 2006-2015 indicates that neurology assets have a 57% likelihood of Ph 3 success and that there is a 73% likelihood of Ph 3 success for non-oncology rare disease assets.
https://www.bio.org/sites/default/f...6-2015 - BIO, Biomedtracker, Amplion 2016.pdf
Release Today Neuren Valuation Estimate Raised, page-26
Add to My Watchlist
What is My Watchlist?
